Overview
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are retinal conditions that are the leading causes of vision loss worldwide. Optimal treatment outcomes depend on patient adherence, timely treatment initiation, and continuation of therapy, which underscores the importance of tailored management strategies. Recent therapy advancements include intravitreal agents with improved durability allowing for increased time between injections. Managed care professionals are uniquely positioned to ensure the safe and effective use of these medications while facilitating the exchange of information between pharmacists and physicians. With an enhanced understanding of the current landscape and treatment strategies for nAMD and DME, managed care professionals can effectively analyze current drug formularies and actively implement new treatment options. This activity will review current and emerging treatment options, therapeutic challenges, and the role of managed care professionals in optimizing management for nAMD and DME. Overall, managed care professionals will be better informed about clinical decisions, which can lead to improved patient outcomes and quality of life.
Learning Objectives
At the completion of this activity, participants will be able to:
- Explore the latest research on innovative therapies for managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Analyze new treatment approaches that can decrease the burden of care for patients with nAMD and DME.
- Identify the best practices for managed care professionals to integrate recent updates to their practice and enhance outcomes for patients with nAMD and DME.
Arghavan Almony, MD
Senior Retina Partner and Vice President Carolina Eye Associates, PA
Southern Pines, North Carolina
Adjunct Assistant Professor
Campbell University School of Medicine
Lillington, North Carolina
Disclosures: Consultant: Cardinal Health
Khalid M. Kamal, MPharm, PhD
Professor and Chair
Department of Pharmaceutical Systems and Policy
West Virginia University School of Pharmacy
Morgantown, West Virginia
Disclosures: Grant/Research Support: Cerevel Therapeutics, EMD Serono; Consultant: Pfizer/Cytel Inc
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times® Editorial Staff— Aislinn Antrim
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms